Global Insulin Syringes Market to Reach $2.40 Billion by 2030

Allied Market Research has published a new report titled "Insulin Syringes Market: Global Opportunity Analysis and Industry Forecast, 2021-2030." The report reveals that the global insulin syringes market, valued at $1,561.20 million in 2020, is projected to reach $2,401.51 million by 2030, registering a compound annual growth rate (CAGR) of 4.4% during the forecast period.

Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/3740

Market Overview

Insulin syringes are critical medical devices used for delivering precise insulin doses to diabetic patients. Comprising three key components - a needle, a barrel, and a plunger - these devices are available in various sizes to accommodate different dosage requirements. The barrel is calibrated in insulin units to ensure accurate dosing, while fine, silicone-coated needles minimize patient discomfort.

The rising global burden of diabetes, fueled by an increasingly aging population, sedentary lifestyles, and growing obesity rates, remains the primary engine of market expansion. Favorable government policies and continuous product innovation, including the development of prefilled insulin syringes, further reinforce demand.

Key Market Drivers

• Surge in aging population and rising global incidence of diabetes, with approximately 462 million individuals affected by type-2 diabetes as of 2019, per the World Health Organization.

• Growing prevalence of obesity and unhealthy lifestyle habits that contribute to the onset of both type-1 and type-2 diabetes.

• Favorable government policies promoting insulin access and subsidized diabetes care in emerging markets.

• Technological advancements such as prefilled insulin syringes improving patient convenience and adherence.

• Heightened demand arising from the COVID-19 pandemic, as diabetic patients - a high-risk group - required uninterrupted access to insulin delivery devices.

Market Restraints

Despite robust growth prospects, the market faces certain headwinds. The increasing adoption of insulin pens as a more user-friendly alternative to traditional syringes, along with the high cost of advanced insulin delivery devices, may temper the pace of expansion in developed markets.

Nevertheless, emerging economies continue to offer significant untapped growth opportunities for market participants.

Market Segmentation Insights

By Syringe Size

The 3/10 cc syringe (0.3 ml) segment dominated the market in 2020 and is projected to maintain its leadership throughout the forecast period. The high prevalence of diabetes and obesity in developing countries is a key factor driving demand for this syringe size.

By Disease Type

The type-2 diabetes segment represented the largest revenue share in 2020. This dominance reflects the global rise in type-2 diabetes cases, attributed primarily to lifestyle changes and dietary habits across both developed and developing nations.

By End User

Hospitals and clinics commanded the leading end-user share in 2020. Rising chronic disease prevalence and a growing geriatric population - with 14.3 million Americans over age 65 living with diabetes as of 2019, per the American Diabetes Association - continue to drive institutional demand.

Regional Analysis

North America held the dominant market position in 2020, driven by increasing diabetes prevalence, robust healthcare infrastructure, and active new product launches by key market players. Asia-Pacific is expected to emerge as the fastest-growing region during the forecast period, owing to a rapidly expanding patient population, improving healthcare access, and rising awareness of diabetes management.

COVID-19 Impact

The COVID-19 pandemic had an overall positive impact on the insulin syringes market. Diabetic patients, who face heightened vulnerability to severe COVID-19 complications, required continuous and uninterrupted access to insulin and monitoring devices. Companies adapted by expanding distribution through online portals, hospital pharmacies, and emergency medical supply chains. Programs such as Eli Lilly's Diabetes Solution Center provided free insulin to financially affected patients, underscoring the industry's commitment to patient care during the crisis.

Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/3740

Key Market Players

The report profiles the following major companies operating in the global insulin syringes market:

• Novo Nordisk A/S

• Biocon Ltd

• Abbott Laboratories

• Terumo Corporation

• Cardinal Health Inc

• Becton, Dickinson and Company

• Eli Lilly and Company

• Nipro Medical Corporation

• Medline Industries

• Hindustan Syringes and Medical Devices Ltd.

Media Contact

Allied Market Research

Tel (US): +1-503-894-6022

Tel (UK): +44-845-528-1300

Tel (India): +91-20-6634-6060

Email: help@alliedmarketresearch.com

Website: www.alliedmarketresearch.com

About Allied Market Research

Allied Market Research (AMR) is a full-service market research and business consulting division of Allied Analytics LLP. AMR provides global enterprises and medium and small businesses with unmatched quality market research reports and business intelligence solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

This release was published on openPR.